Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress65% of patients with clinically significant portal hypertension (CSPH) at baseline moved into lower risk categories by year twoPatients achieved a mean 6.7 kPa reduction in liver stiffness, which was statistically significant compared to baseline CONSHOHOCKEN, Pa., May 10, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced positive two-year results from the open-label compensated MA

First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as oral late-breaker at EASL Congress (May 7-10)Appointed David Soergel, M.D., to Chief Medical Officer; Rebecca Taub, M.D., named Senior Scientific and Medical Advisor Appointed Jacqualyn Fouse, Ph.D., to Board of DirectorsReports cash, cash equivalents, restricted cash and marketable securities of $848.1 million at March 31, 2025Company to host conference call today, May 1, 2025, at 8 a.m. EDT CONSHOHOCKEN, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc.

CONSHOHOCKEN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced six presentations at the upcoming European Association for the Study of the Liver (EASL) Congress, taking place from May 7-10, 2025, in Amsterdam, the Netherlands. Madrigal will share detailed two-year data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial in a late-breaking oral presentation titled, "Treatment with resmetirom for up to two years led to improvement in liver stiffness, fibrosis biomarkers,

CONSHOHOCKEN, Pa., April 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its first-quarter 2025 financial results on Thursday, May 1, 2025, prior to the open of the U.S. financial markets. Following the announcement, Madrigal's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results. The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended t

CONSHOHOCKEN, Pa., April 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that Rebecca Taub, M.D., the company's founder, Chief Medical Officer, and President of Research & Development (R&D), will transition to the role of Senior Scientific and Medical Advisor. Dr. Taub will continue to serve on Madrigal's Board of Directors. Succeeding her, David Soergel, M.D., has been appointed Executive Vice President, Chief Medical Officer, effective April 21, 2025. After teaching Genetics and Medicine at the University of Pennsy

Fred Craves, Ph.D. to retire from Madrigal's Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed Jacqualyn ("Jackie") Fouse, Ph.D. to its Board of Directors. Fred Craves, Ph.D. is retiring from the Board in July 2025. Julian Baker, Chairman of the Board of Directors, stated, "I am delighted to welcome Jackie Fouse to Madrigal. Jackie is an accomplished biotech executive who brings more than 30 years of healthcare industry and finance experience

Fourth-quarter and full-year 2024 Rezdiffra net sales of $103.3 million and $180.1 million, respectivelyAs of year-end 2024, more than 11,800 patients on Rezdiffra Reports cash, cash equivalents, restricted cash and marketable securities of $931.3 million at December 31, 2024Announces new two-year data for the active-treatment open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial Company to host conference call today, February 26, 2025, at 8 a.m. EST CONSHOHOCKEN, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated stea

Patients achieved a mean 6.7 kPa reduction in liver stiffness as measured by vibration-controlled transient elastography (VCTE); this represents the largest reduction in liver stiffness reported in a compensated MASH cirrhosis patient population 51% of patients achieved a ≥25% reduction in liver stiffness; a reduction of this magnitude has been associated with reduced progression to end-stage liver diseaseCompany to review topline data during its fourth-quarter and full-year 2024 financial results conference call today, February 26, 2025, at 8 a.m. EST CONSHOHOCKEN, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused

CONSHOHOCKEN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025 at 11:10 A.M. ET. The presentation will be webcast live and may be accessed here or by visiting Madrigal's Investor Relations Events page. A replay of the webcast will be available after the event. About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal's medicati

CONSHOHOCKEN, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it will release its fourth-quarter and full-year 2024 financial results on Wednesday, Feb. 26, 2025, prior to the open of the U.S. financial markets. Following the announcement, Madrigal's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results. The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register here at least 15 minutes prior to the scheduled webcast. The webcast will b

Fred Craves, Ph.D. to retire from Madrigal's Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed Jacqualyn ("Jackie") Fouse, Ph.D. to its Board of Directors. Fred Craves, Ph.D. is retiring from the Board in July 2025. Julian Baker, Chairman of the Board of Directors, stated, "I am delighted to welcome Jackie Fouse to Madrigal. Jackie is an accomplished biotech executive who brings more than 30 years of healthcare industry and finance experience

CONSHOHOCKEN, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced the appointment of Michael R. Charlton, M.B.B.S., F.R.C.P., as Senior Vice President, Clinical Development, effective October 1, 2024. Becky Taub, M.D., Chief Medical Officer and President of Research & Development of Madrigal, stated, "I am thrilled to have Dr. Charlton joining the Madrigal team; his deep experience as a researcher and clinician treating patients with NASH will bring powerful new insights and ca

CONSHOHOCKEN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the appointment of Shannon Kelley as General Counsel, effective August 5, 2024. Bill Sibold, Chief Executive Officer of Madrigal, stated, "Shannon is an outstanding leader who brings a wealth of expertise to her new role as General Counsel. She joined the Madrigal team in 2024 as Chief Compliance Officer and played an instrumental role guiding the company through a period of rapid growth. I feel privileged to be working with Shannon and the other members of our leader

CONSHOHOCKEN, Pa., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Ronald Filippo has been appointed Chief Information Officer. Mr. Filippo has more than 25 years of digital experience in the biopharmaceutical industry and was previously Senior Vice President Digital at Moderna, where he was responsible for technology leadership and digital transformation across core operations during the commercialization of the company's COVID-19 vaccine. Bill Sibold, Chief Executive Officer of Madrigal, stated, "Ron's skillset and depth of

CONSHOHOCKEN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Carole Huntsman has been appointed Chief Commercial Officer. Ms. Huntsman was most recently Senior Vice President, Head of Specialty Care North America and U.S. Country Lead at Sanofi, where she directed 2,600 team members across multiple product launches in immunology, neurology, oncology, rare diseases, and rare blood disorders. This included executing the launch of Dupixent, a first-in-class therapy which has grown into an industry-leading medicine. In 2022,

CONSHOHOCKEN, Pa., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that it made an inducement grant to Bill Sibold on September 11, 2023 in connection with his appointment as Madrigal's new President and Chief Executive Officer. The award was granted outside of the company's Amended 2015 Stock Plan under the terms of the company's 2023 Inducement Plan (which was approved and adopted by the Board of Directors on September 8, 2023) and was approved by the company's Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)

CONSHOHOCKEN, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Bill Sibold has succeeded Paul Friedman, M.D., as Chief Executive Officer (CEO) and joined Madrigal's Board of Directors. Dr. Friedman, who has served as Madrigal's CEO since 2016, will continue to serve on the Board of Directors. Julian Baker, Chairman of the Board of Directors, stated, "On behalf of the Board, I want to thank Dr. Paul Friedman for the remarkable success that Madrigal has achieved during his tenure as CEO. Paul has built an outstanding team

Submission status for MADRIGAL PHARMACEUTICALS INC's drug REZDIFFRA (ORIG-1) with active ingredient RESMETIROM has changed to 'Approval' on 03/14/2024. Application Category: NDA, Application Number: 217785, Application Classification: Type 1 - New Molecular Entity

4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

SC 13G/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

SC 13G - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

SC 13D/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

SC 13G/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

SC 13G/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

SC 13G/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

SC 13G/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

SC 13D/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

SC 13D/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

SC 13G - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

B. Riley Securities upgraded Madrigal Pharmaceuticals from Neutral to Buy and set a new price target of $422.00 from $236.00 previously

H.C. Wainwright reiterated coverage of Madrigal Pharmaceuticals with a rating of Buy and set a new price target of $405.00 from $400.00 previously

Cantor Fitzgerald initiated coverage of Madrigal Pharmaceuticals with a rating of Neutral

Wolfe Research initiated coverage of Madrigal Pharmaceuticals with a rating of Outperform and set a new price target of $382.00

BofA Securities initiated coverage of Madrigal Pharmaceuticals with a rating of Underperform and set a new price target of $150.00

B. Riley Securities upgraded Madrigal Pharmaceuticals from Sell to Neutral and set a new price target of $270.00 from $155.00 previously

Citigroup initiated coverage of Madrigal Pharmaceuticals with a rating of Buy and set a new price target of $382.00

B. Riley Securities downgraded Madrigal Pharmaceuticals from Neutral to Sell and set a new price target of $155.00

Oppenheimer reiterated coverage of Madrigal Pharmaceuticals with a rating of Outperform and set a new price target of $250.00 from $170.00 previously

Raymond James upgraded Madrigal Pharmaceuticals from Underperform to Mkt Perform

4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

3 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

3 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as oral late-breaker at EASL Congress (May 7-10)Appointed David Soergel, M.D., to Chief Medical Officer; Rebecca Taub, M.D., named Senior Scientific and Medical Advisor Appointed Jacqualyn Fouse, Ph.D., to Board of DirectorsReports cash, cash equivalents, restricted cash and marketable securities of $848.1 million at March 31, 2025Company to host conference call today, May 1, 2025, at 8 a.m. EDT CONSHOHOCKEN, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc.

Patients achieved a mean 6.7 kPa reduction in liver stiffness as measured by vibration-controlled transient elastography (VCTE); this represents the largest reduction in liver stiffness reported in a compensated MASH cirrhosis patient population 51% of patients achieved a ≥25% reduction in liver stiffness; a reduction of this magnitude has been associated with reduced progression to end-stage liver diseaseCompany to review topline data during its fourth-quarter and full-year 2024 financial results conference call today, February 26, 2025, at 8 a.m. EST CONSHOHOCKEN, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused

Third-quarter 2024 net sales of $62.2 million Rezdiffra™ (resmetirom) coverage goal achieved early, with more than 80 percent of commercial lives covered; less than 5 percent of Rezdiffra-covered lives require biopsy Completed enrollment of clinical outcomes study of Rezdiffra in patients with compensated NASH/MASH cirrhosisReports cash, cash equivalents, restricted cash and marketable securities of $1.0 billion at September 30, 2024Company to host conference call today, October 31, 2024, at 8 a.m. EDT CONSHOHOCKEN, Pa., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic stea

Rezdiffra becomes the first and only medication approved by the FDA for the treatment of NASH (also known as "MASH")Accelerated approval was based on Phase 3 data demonstrating that Rezdiffra improved liver fibrosis and resolved NASH in patients with noncirrhotic NASH with moderate to advanced liver fibrosis Rezdiffra prescribing information does not include a liver biopsy requirement for diagnosisMadrigal conference call scheduled for March 14, 2024, at 5:15 pm ET CONSHOHOCKEN, Pa., March 14, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced t

In MAESTRO-NASH, a 52-week serial liver biopsy Phase 3 study in more than 950 patients, resmetirom achieved both primary endpoints and potentially clinically meaningful effects with both daily oral doses, 80 mg and 100 mg, relative to placebo NASH resolution (ballooning of 0, inflammation of 0-1) and ≥2-point NAS reduction with no worsening of fibrosis (p<0.0001 at both doses)Fibrosis improvement by at least one stage with no worsening of NAS (p=0.0002 and <0.0001 at 80 and 100 mg, respectively) Potentially clinically meaningful LDL-lowering, a key secondary endpoint (p<0.0001)Multiple positive effects on NASH biomarkers and imaging Resmetirom was safe and well-tolerated in the MAESTRO

CONSHOHOCKEN, Pa., Dec. 18, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), plans to announce topline results from the Phase 3 MAESTRO-NASH study of resmetirom on Monday, December 19th, 2022. The schedule for the press release and conference call/webcast is as follows: • MAESTRO-NASH Press Release: December 19th, 2022 at 7:00 am EST• MAESTRO-NAFLD-1 Conference Call:   December 19th, 2022 at 8:00 am EST    To access the live webcast of the call with slides please visit the Investors section of Madrigal's website or click here. To access the call by phone, p

MAESTRO-NAFLD-1 late-breaker and three other Madrigal abstracts accepted for oral presentation at the EASL International Liver Congress™Data from the Phase 3 MAESTRO-NAFLD-1 study continue to reinforce the safety and efficacy profiles of resmetiromMadrigal remains on track to disclose topline data from MAESTRO-NASH in the fourth quarter and anticipates filing for accelerated approval under Subpart H next yearPlanned MAESTRO-NASH Outcomes trial, a non-invasive Phase 3 study designed to accelerate the full approval timeline for non-cirrhotic NASH, will evaluate resmetirom effects on liver decompensation events in patients with early NASH cirrhosis Madrigal enters into term loan facility with a

CONSHOHOCKEN, Pa., April 28, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), will report its first quarter 2022 financial results on Monday, May 9, 2022 and provide business and clinical program updates with some additional results from the Phase 3 MAESTRO-NAFLD-1 study. The schedule for the press release and conference call/webcast is as follows: Press Release:May 9th, 2022 at 6:30 am ETConference Call:May 9th, 2022 at 8:00 am ET• Domestic Dial-In Number:(833) 660-2754• International Dial-In Number:(409) 350-3497• Conference ID Number:9765409 To access t

Primary and key secondary endpoints from the double-blind placebo-controlled 969-patient MAESTRO-NAFLD-1 safety study were achieved and demonstrate that resmetirom: Was safe and well-tolerated at 80 and 100 mg in patients treated for 52 weeksProvided significant and clinically relevant reductions in liver fat as measured by magnetic resonance imaging proton density fat-fraction (MRI-PDFF)Significantly reduced atherogenic lipids, including LDLc, apolipoprotein B and triglycerides The increased enrollment of patients into the safety database is consistent with meeting regulatory guidance for chronic disease therapies Madrigal to host conference call at 8:00 am EST to review the data CONSHO

CONSHOHOCKEN, Pa., Jan. 30, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, plans to announce topline results from the Phase 3 MAESTRO-NAFLD-1 study of resmetirom on Monday, January 31st, 2022. The schedule for the press release and conference call/webcast is as follows: • MAESTRO-NAFLD-1 Press Release:  January 31st, 2022 at 7:00 am EST• MAESTRO-NAFLD-1 Conference Call:  January 31st, 2022 at 8:00 am EST• Domestic Dial-In Number:  (833) 660-2754• International Dial-In Number:   (409) 350-3497• Conference ID Number: 9170277 To access the live webcast of the call please v